Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker

Jang, Ju Hye; Kim, Min Young; Lee, Jin-Won; Kim, Sun Chang; Cho, Ju Hyun

doi:10.1016/j.peptides.2011.02.010

Cited by 34 publications

(23 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Molecules that inhibit matrix metalloproteinases (MMPs) activity are also interesting potential drugs (Destouches et al, 2012). MMPs are a family of membrane-bound zinc endopeptidases that display an important activity in what concerns remodeling of the extracellular matrix (ECM) in processes as tumor development, angiogenesis and metastatic progression (Coussens and Werb, 2002; Coussens et al, 2002; Egeblad and Werb, 2002; Visse and Nagase, 2003; Jang et al, 2011; Destouches et al, 2012). Many cancers express aberrant MMPs quantities (Derrico et al, 1991; Davies et al, 1993) and this fact can be used for creating strategies to block metastasis process.…”

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

“…For instance, buforin IIb, that displays activity against 60 human tumor cell lines (Lee et al, 2008), was fused with a modified magainin sequence, a negative charge that would equilibrate the overall positive charge of buforin II, generating the MMIS:buforin IIb fusion peptide. Both peptide sequences were in turn linked by an octapeptide, cleavable by the MMP-2 (gelatinase A) and MMP-9 (gelatinase B) enzymes which are over expressed in tumor tissues, allowing the release of buforin IIb (Jang et al, 2011). Cells expressing high amounts of MMPs such as mouse melanoma, human fibrosarcoma and gliobastoma were sensitive to this peptide.…”

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

“…Cells expressing high amounts of MMPs such as mouse melanoma, human fibrosarcoma and gliobastoma were sensitive to this peptide. On the other hand, human uterine cervix cells which deficiently express these MMPs were resistant, and the fusion peptide anticancer activity was shown to be dependent on enzymatic activity (Jang et al, 2011). Two final different examples concerns to tachyplesin and temporin-1CEa.…”

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

See 2 more Smart Citations

From antimicrobial to anticancer peptides. A review

Gaspar¹,

Veiga²,

Castanho³

2013

Front. Microbiol.

624

553

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs) are part of the innate immune defense mechanism of many organisms. Although AMPs have been essentially studied and developed as potential alternatives for fighting infectious diseases, their use as anticancer peptides (ACPs) in cancer therapy either alone or in combination with other conventional drugs has been regarded as a therapeutic strategy to explore. As human cancer remains a cause of high morbidity and mortality worldwide, an urgent need of new, selective, and more efficient drugs is evident. Even though ACPs are expected to be selective toward tumor cells without impairing the normal body physiological functions, the development of a selective ACP has been a challenge. It is not yet possible to predict antitumor activity based on ACPs structures. ACPs are unique molecules when compared to the actual chemotherapeutic arsenal available for cancer treatment and display a variety of modes of action which in some types of cancer seem to co-exist. Regardless the debate surrounding the definition of structure-activity relationships for ACPs, great effort has been invested in ACP design and the challenge of improving effective killing of tumor cells remains. As detailed studies on ACPs mechanisms of action are crucial for optimizing drug development, in this review we provide an overview of the literature concerning peptides' structure, modes of action, selectivity, and efficacy and also summarize some of the many ACPs studied and/or developed for targeting different solid and hematologic malignancies with special emphasis on the first group. Strategies described for drug development and for increasing peptide selectivity toward specific cells while reducing toxicity are also discussed.

show abstract

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

Section: Anticancer Peptides For Solid and Hematological Tumorsmentioning

confidence: 99%

See 1 more Smart Citation

From antimicrobial to anticancer peptides. A review

Gaspar¹,

Veiga²,

Castanho³

2013

Front. Microbiol.

624

553

View full text Add to dashboard Cite

show abstract

“…Hemolytic activity was assayed as described by Jang et al with a slight modification [19]. Briefly, three milliliters of freshly prepared human red blood cells (RBCs) were washed with PBS, pH 7.4, until the color of the supernatant turned clear.…”

Section: Hemolysis Assaymentioning

confidence: 99%

Enhancement of the antimicrobial activity and selectivity of GNU7 against Gram-negative bacteria by fusion with LPS-targeting peptide

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…Modern chemotherapy based on synthetic oligo peptides provides an effective anti-metastasis medication for patients with tumors, exhibiting high affinity and low toxicity (13–16). P-5m is an octapeptide derived from domain 5 of high-molecular weight kininogen; the P-5m peptide has been indicated to promote the inhibition of metastatic activity exhibited in human melanoma cells (17).…”

Section: Introductionmentioning

confidence: 99%

Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Han

Yan

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

The present study has demonstrated that P-5m octapeptide (P-5m) has therapeutic potential in metastatic human hepatocarcinoma, possibly through the modulation of matrix metalloproteinase-2 expression. The purpose of the present study was to evaluate the antitumor effect of P-5m combined with 5-fluorouracil (5-Fu) on the treatment of hepatoma 22 (H22) hepatocarcinoma malignant ascites in a mouse model. The inhibitory effect on the growth of mouse ascites tumors was monitored by measuring body weight gain, survival time, ascites volume, numbers of tumor cells, DNA synthesis and peritoneal capillary permeability analysis. The present data revealed a significant reduction in ascites volume and cell count in mice that were treated with P-5m plus 5-Fu. Furthermore, the median survival time in mice in the combination group was prolonged compared with the disease control group. Moreover, a significant reduction in the total H22 ascites cell count in mice from the combination group was observed when compared with the disease control group. P-5m plus 5-Fu was able to induce the cell cycle arrest and inhibit the peritoneal capillary permeability of the mice. To conclude, the present study indicated that P-5m may have therapeutic potential in ascites caused by hepatocellular carcinoma.

show abstract

Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker

Cited by 34 publications

References 27 publications

From antimicrobial to anticancer peptides. A review

From antimicrobial to anticancer peptides. A review

Enhancement of the antimicrobial activity and selectivity of GNU7 against Gram-negative bacteria by fusion with LPS-targeting peptide

Combined antitumor effects of P‑5m octapeptide and 5‑fluorouracil on a murine model of H22 hepatoma ascites

Contact Info

Product

Resources

About